XTX Topco Ltd Invests $674,000 in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

XTX Topco Ltd purchased a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 13,891 shares of the company’s stock, valued at approximately $674,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Aurora Investment Counsel raised its stake in shares of Amphastar Pharmaceuticals by 0.4% in the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company’s stock valued at $2,654,000 after acquiring an additional 232 shares during the last quarter. GAMMA Investing LLC raised its position in Amphastar Pharmaceuticals by 70.0% in the 3rd quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after purchasing an additional 273 shares during the last quarter. Crossmark Global Holdings Inc. boosted its stake in Amphastar Pharmaceuticals by 2.5% in the second quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock worth $452,000 after purchasing an additional 275 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock worth $85,000 after purchasing an additional 301 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after buying an additional 309 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

Shares of AMPH stock opened at $44.50 on Friday. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of 14.83, a PEG ratio of 0.87 and a beta of 0.78. Amphastar Pharmaceuticals, Inc. has a 12 month low of $36.56 and a 12 month high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a 50-day moving average price of $47.22 and a 200 day moving average price of $44.62.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the stock. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Wells Fargo & Company assumed coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 target price on the stock. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $60.33.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total value of $244,000.00. Following the transaction, the director now directly owns 31,471 shares of the company’s stock, valued at approximately $1,535,784.80. This trade represents a 13.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the transaction, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. This trade represents a 6.51 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 34,533 shares of company stock worth $1,676,542 in the last quarter. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.